Nazarin Nazari Yana Nuna Aminci da Ingantattun Magungunan CAR-T wajen Magance Malignancies na B-Cell
Wani bincike na baya-bayan nan da Dokta Zhi-tao Ying ya jagoranta daga Asibitin Ciwon daji na Jami'ar Peking ya nuna sakamako mai ban sha'awa a cikin jiyya na sake dawowa da rashin lafiyar jini na B-cell ta hanyar amfani da sabon maganin antigen receptor T (CAR-T), IM19. An buga a cikinJaridar Sinawa ta Sabbin Magunguna, Binciken ya nuna mahimmancin yiwuwar maganin warkewa na IM19 a cikin marasa lafiya waɗanda suka ƙare zaɓuɓɓukan magani na al'ada.
Binciken ya ƙunshi marasa lafiya 12, daidai da rarraba tsakanin waɗanda ke fama da cutar sankarar bargo na B-cell ba Hodgkin (NHL) da kuma cutar sankarar bargo na B-cell lymphoblastic (B-ALL). An bi da marasa lafiya tare da nau'ikan nau'ikan nau'ikan IM19 CAR-T, waɗanda aka ba su bayan tsarin yanayin yanayin da ya ƙunshi fludarabine da cyclophosphamide. Maƙasudin ƙarshen binciken sun haɗa da kimanta ƙimar amsa gabaɗaya, dagewar ƙwayoyin CAR-T, sakin cytokine, da saka idanu mara kyau.
(Hoto yana nuna dawo da NHL da B-ALL marasa lafiya)
Abin sha'awa, 11 daga cikin marasa lafiya 12 sun sami cikakkiyar gafara, tare da yaduwa na IM19 a cikin jininsu. Maganin ya haifar da karuwa a cikin cytokines irin su interleukin-6 da interleukin-10, yana nuna amsawar rigakafi mai ƙarfi. Mahimmanci, babu ɗayan majiyyatan da ya sami ciwo mai tsanani na sakin cytokine ko ƙwayar cuta mai alaƙa da CAR-T, wanda ke nuna kyakkyawan bayanin lafiyar maganin.
Tawagar hadin gwiwa daga Asibitin Cancer na Jami'ar Peking, Asibitin Hebei Yanda Lu Daopei, da Peking Pharmaceuticals ne suka gudanar da binciken. Dokta Ying, marubucin jagora, ya ƙware a cikin bincike da kuma maganin cutar sankarau, yayin da Dr. Jun Zhu, marubucin da ya dace, ya kasance sanannen ƙwararre a wannan fanni. An tallafa wa wannan binciken daga manyan tallafi da dama, ciki har da gidauniyar kimiyyar dabi'a ta kasar Sin da gidauniyar kimiyyar dabi'a ta Beijing.
Wannan binciken mai ban sha'awa yana ba da shaida mai mahimmanci cewa IM19 CAR-T far ba kawai tasiri ba ne amma kuma lafiya ga marasa lafiya tare da ƙalubalen ƙwayoyin cuta na B-cell. Yana buɗe hanya don bincike na gaba da yuwuwar aikace-aikacen asibiti, yana ba da sabon bege ga marasa lafiya waɗanda ke da iyakacin zaɓuɓɓukan magani.